what are your predictions for Fuze Medical....?
Post# of 36537
(Total Views: 360)
Posted On: 05/04/2019 8:15:42 AM
what are your predictions for Fuze Medical....?
...this is a profitable company...and designated as 'penny stock exempt''.....that is a great accomplishment by the ceo and board to achieve such results.....noway this is going to be a pool shares acquisition, but it is....u would have to be a miracle man to do this deal.....i guess we have that covered .....
Fuze Medical Financials, from:
https://www.businesswire.com/news/home/201903...-Financial
2018 Financial Highlights
Net revenue of $26.3 million
Gross profit increase by 10% to $13 million
Record net income of $4.0 million, or 15% of net revenues
Earnings per share of $0.06 compared to $0.04 for 2017,on a diluted basis
EBITDA of $4.6 million, an increase of $3.6 million over 2017(1)
Net cash flows provided by operations, an increase of 55% to $2.5 million (1)
2018 Strategic Milestones
Listed as “Penny Stock Exempt” by OTC Markets
Recognized as No. 56 of the fastest growing companies in the Deloitte 2018 Technology Fast 500TM
Ranked as the 143rd largest public company by revenue in the Dallas-Fort Worth metropolitan area by the Dallas Morning News
Completed the acquisition and integration of CPM Medical Consultants, LLC & Palm Springs Partners, LLC d/b/a Maxim Surgical
Established Scientific Advisory Boards with Key Opinion Leaders to assist with our product development and design input
...this is a profitable company...and designated as 'penny stock exempt''.....that is a great accomplishment by the ceo and board to achieve such results.....noway this is going to be a pool shares acquisition, but it is....u would have to be a miracle man to do this deal.....i guess we have that covered .....
Fuze Medical Financials, from:
https://www.businesswire.com/news/home/201903...-Financial
2018 Financial Highlights
Net revenue of $26.3 million
Gross profit increase by 10% to $13 million
Record net income of $4.0 million, or 15% of net revenues
Earnings per share of $0.06 compared to $0.04 for 2017,on a diluted basis
EBITDA of $4.6 million, an increase of $3.6 million over 2017(1)
Net cash flows provided by operations, an increase of 55% to $2.5 million (1)
2018 Strategic Milestones
Listed as “Penny Stock Exempt” by OTC Markets
Recognized as No. 56 of the fastest growing companies in the Deloitte 2018 Technology Fast 500TM
Ranked as the 143rd largest public company by revenue in the Dallas-Fort Worth metropolitan area by the Dallas Morning News
Completed the acquisition and integration of CPM Medical Consultants, LLC & Palm Springs Partners, LLC d/b/a Maxim Surgical
Established Scientific Advisory Boards with Key Opinion Leaders to assist with our product development and design input
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼